Physician profile
Vikas Jindal
NPI 1033126321
$7,083.82
in general payments reported to CMS, 2019-2025
36 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $229 · 2021: $617 · 2022: $1,095 · 2023: $1,479 · 2024: $1,688 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,609.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $969.35 | 2019-2025 | |
| Amgen INC. | $846.96 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $710.46 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $584.80 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $543.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $378.95 | 2023-2025 | Evkeeza, Praluent |
| Lexicon Pharmaceuticals, INC. | $348.70 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $343.06 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $319.65 | 2019-2024 | Xarelto |
| Pfizer INC. | $253.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.78 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.26 | 2022-2025 | Lifevest |
| Heartflow, INC. | $160.90 | 2022-2025 | Ffrct |
| Amarin Pharma, INC. | $160.20 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $132.08 | 2024 | Arcalyst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $92.69 | 2022-2023 | Onpattro |
| Sanofi-Aventis U.S. LLC | $85.53 | 2019-2023 | |
| Genzyme Corporation | $81.61 | 2023 | |
| Cvrx, INC. | $75.71 | 2024-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $65.35 | 2023 | Optimizer |
| Boston Scientific Corporation | $62.26 | 2022-2025 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $62.03 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Potrero Medical, INC. | $49.63 | 2021 | |
| Lilly USA, LLC | $44.46 | 2024 | Zepbound, Jardiance |
| Bard Peripheral Vascular, INC. | $42.19 | 2023 | Lutonix Drug Coated Balloon |
| Bayer Healthcare Pharmaceuticals INC. | $41.76 | 2021-2022 | |
| Scpharmaceuticals INC. | $36.70 | 2023-2024 | |
| Recor Medical INC | $35.72 | 2025 | Paradise Ultrasound Renal Denervation System |
| Baxter Healthcare | $30.49 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medicure Pharma INC. | $28.32 | 2021-2023 | Zypitamag |
| Actelion Pharmaceuticals US, INC. | $27.68 | 2019 | |
| Amryt Pharma Holdings LTD | $24.80 | 2022 | |
| Astellas Pharma US INC | $19.80 | 2019 | |
| Amicus Therapeutics, INC. | $19.34 | 2021 | |
| G Medical Diagnostic Services, INC. | $14.07 | 2023 | Cardiac Monitoring Suite |
| Bardy Diagnostics, INC. | $2.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.